Section 5. 510(k) Summary

1. Administrative

Device Information
Device Name: ABL90 Flex
Common Name: Blood gases and blood pH test system
Product Code: CHL (JGS, CEM, JFP, CGZ, CGA, KHP, GKR, GHS, KQI, JJY, JIX)
Registration Number: 21 CFR 862.1120
Classification: Class II
Classification Panel: Clinical Chemistry

Submitter
Company Name: Radiometer Medical ApS
ER Number: 3002807968
Address: Aakandevej 21
2700 Broenshoej
Denmark
Phone: +45 3827 3827
Fax: +45 3827 2727

2. Description of Device Modification

The ABL90 Flex is a portable, automated system intended for in vitro testing of samples of whole blood for the parameters pH, pO2, pCO2, potassium, sodium, calcium, chloride, glucose, lactate, and co-oximetry parameters (total hemoglobin, oxygen saturation, and the hemoglobin fractions F02Hb, FCOHb, F MetHb, FHHb and FHbf).

The existing ABL90 Flex analyzer has been equipped with rechargeable batteries and the analyzer software has been updated to control the charging of the battery and to provide indication regarding the charging status and level.

3. Intended Use

The ABL90 Flex is a portable, automated analyzer that measures pH, blood gases, electrolytes, glucose, lactate and oximetry in whole blood. The ABL90 Flex is intended for use by trained technologists, nurses, physicians and therapists. It is intended for use in a laboratory environment, near patient or point-of-care setting.

4. Substantial Equivalence

The ABL90 Flex with the Battery Option is substantially equivalent in Intended Use, fundamental scientific technology, features, and characteristics to the predicate:

510(k) Number/Device Manufacturer:
K092686 ABL90 Flex, Radiometer Medical ApS
**Predicate: ABL90 Flex (K092686)**

<table>
<thead>
<tr>
<th>Similarities</th>
<th>Differences</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intended Use (The ABL90 FLEX is a portable, automated analyzer that measures pH, blood gases, electrolytes, glucose, lactate and oximetry in whole blood. The ABL90 FLEX is intended for use by trained technologists, nurses, physicians and therapists. It is intended for use in a laboratory environment, near patient or point-of-care setting.)</td>
<td>Internal Power Source Battery Pack with charger unit Input: 24 Vdc, 48W Output: 24Vdc, 2250mAh</td>
</tr>
<tr>
<td>Blood Gas Measurement (pH, pO₂, pCO₂ by potentiometry)</td>
<td>Light Emitting Diodes (green and yellow) in analyzer socket</td>
</tr>
<tr>
<td>Electrolyte Measurement (cK⁺, cNa⁺, cCa²⁺, cCl⁻ by potentiometry)</td>
<td>Battery status and charging symbols on analyzer screen</td>
</tr>
<tr>
<td>Metabolite Measurement (cGlu, cLac by amperometry)</td>
<td>Increased by ca. 600g compared to ABL90 Flex (K092686)</td>
</tr>
<tr>
<td>Oximetry Measurement (ctHb, sO₂, FO₂, Hb, FHHb, FCOHb, FMethb, FHHb)</td>
<td></td>
</tr>
<tr>
<td>Hemoglobin Measurement (Spectrophotometry)</td>
<td></td>
</tr>
<tr>
<td>Identical Performance Characteristics</td>
<td></td>
</tr>
<tr>
<td>Two-Point liquid calibration</td>
<td></td>
</tr>
<tr>
<td>Menu driven touch screen</td>
<td></td>
</tr>
<tr>
<td>Software operating system (Microsoft XPE)</td>
<td></td>
</tr>
<tr>
<td>Sample Introduction Aspiration</td>
<td></td>
</tr>
<tr>
<td>Dimensions (length x width x depth)</td>
<td></td>
</tr>
<tr>
<td>External Power Source 230/120 V mains</td>
<td></td>
</tr>
</tbody>
</table>

5. Performance Data

No performance characteristics are affected by the change. The performance data submitted in K092686 still apply.
Re: k111897
Trade/Device Name: ABL90 Flex Analyzer
Regulation Number: 21 CFR 862.1120
Regulation Name: Blood gases (PCO2, PO2) and blood pH test system.
Regulatory Class: II
Product Code: CHL, JGS, CEM, JFP, CGZ, CGA, KHP, GKR, GHS, KQI, JJY, JIX
Dated: June 29, 2011
Received: July 5, 2011

Dear: Mr. Gabler:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

[Signature]

Courtney Harper, Ph.D.
Director
Division of Chemistry and Toxicology
Office of In Vitro Diagnostic Device Evaluation and Safety
Center for Devices and Radiological Health

Enclosure
Section 4. Indications for Use

510(k) Number (if known): K111897

Device Name: ABL90 Flex Analyzer

The ABL90 FLEX is a portable, automated analyzer that measures pH, blood gases, electrolytes, glucose, lactate and oximetry in heparinized whole blood. The ABL90 FLEX is intended for use by trained technologists, nurses, physicians and therapists. It is intended for use in a laboratory environment, near patient or point-of-care setting.

These tests are only performed under a physician's order:


Potassium (cK+): potassium measurements are used to monitor electrolyte balance in the diagnosis and treatment of disease conditions characterized by low or high blood potassium levels.

Sodium (cNa+): sodium measurements are used in the diagnosis and treatment of aldosteronism, diabetes insipidus, adrenal hypertension, Addison's disease, dehydration, inappropriate antidiuretic secretion, or other diseases involving electrolyte imbalance.

Calcium (cCa2+): calcium measurements are used in the diagnosis and treatment of parathyroid disease, a variety of bone diseases, chronic renal disease and tetany.

Chloride (cCl-): chloride measurements are used in the diagnosis and treatment of electrolyte and metabolic disorders such as cystic fibrosis and diabetic acidosis.

Glucose (cGlu): glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.

Indications for Use: Prescription Use AND/OR Over-The-Counter

X (Part 21 CFR 801 Subpart D)  

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Division Sign-Off Office of In Vitro Diagnostic Devices Evaluation and Safety

510(k) K111897
Section 4. Indications for Use

510(k) Number (if known): K111897
Device Name: ABL90 Flex Analyzer

Lactate (cLac): The lactate measurements measure the concentration of lactate in plasma. Lactate measurements are used to evaluate the acid-base status and are used in the diagnosis and treatment of lactic acidosis (abnormally high acidity of the blood.)

Total Hemoglobin (ctHb): total hemoglobin measurements are used to measure the hemoglobin content of whole blood for the detection of anemia.

sO2: oxygen saturation, more specifically the ratio between the concentration of oxyhemoglobin and oxyhemoglobin plus reduced hemoglobin.

FO2Hb: oxyhemoglobin as a fraction of total hemoglobin.

FCOHb: carboxyhemoglobin measurements are used to determine the carboxyhemoglobin content of human blood as an aid in the diagnosis of carbon monoxide poisoning.

FMetHb: methemoglobin as a fraction of total hemoglobin.

FHHb: reduced hemoglobin as a fraction of total hemoglobin.

Fraction of Fetal Hemoglobin (FHbF): FHbF indicates the amount of fetal hemoglobin. FHbF is seldom used clinically.

Indications for Use: Prescription Use AND/OR Over-The-Counter (Part 21 CFR 801 Subpart D) AND/OR (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K111897